| emricasan (IDN 6556) / Amerimmune |
NCT00088140: A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients |
|
|
| Completed | 2 | 204 | US | IDN-6556, Placebo | Conatus Pharmaceuticals Inc., Idun Pharmaceuticals | Hepatitis C, Chronic | 10/05 | 10/05 | | |
NCT00080236: Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation |
|
|
| Completed | 2 | 99 | US, Europe | IDN-6556, Placebo | Conatus Pharmaceuticals Inc., Idun Pharmaceuticals | Liver Transplantation, Hepatitis, Cholestasis, Carcinoma, Hepatocellular | 01/06 | 01/06 | | |
| Terminated | 2 | 23 | US, Europe | IDN-6556, emricasan, PF-03491390, Placebo | Conatus Pharmaceuticals Inc. | Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirrhosis, Acute Alcoholic Hepatitis | 01/15 | 02/15 | | |
NCT02077374: A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases |
|
|
| Completed | 2 | 38 | US | IDN-6556, emricasan, PF-03491390, Placebo | Conatus Pharmaceuticals Inc. | Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease | 03/15 | 03/15 | | |
NCT02230683: A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension |
|
|
| Completed | 2 | 23 | US | IDN-6556, emricasan, PF-013491390 | Conatus Pharmaceuticals Inc. | Liver Cirrhosis, Hepatic Cirrhosis, Portal Hypertension | 05/15 | 06/15 | | |
NCT01912404: Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy |
|
|
| Terminated | 2 | 5 | US | IDN-6556, emricasan, PF-03491390, Placebo | Conatus Pharmaceuticals Inc., National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcoholic Hepatitis | 08/15 | 08/15 | | |
NCT02230670: A Study of IDN-6556 in Subjects With Liver Cirrhosis |
|
|
| Completed | 2 | 87 | US | IDN-6556, emricasan, PF-03491390, Placebo | Conatus Pharmaceuticals Inc. | Liver Cirrhosis, Hepatic Cirrhosis | 01/16 | 01/16 | | |
